Terapia prechirurgica della fibromatosi uterina - FedOA - Università ...

40. Di Lieto A, De Falco M, Staibano S, Iannotti F, Scaramellino M,
Salvatore G et al. Effects of gonadotropin-releasing hormone agonists
on uterine volume and vasculature and on the immunohistochemical
expression of basic fibroblast growth factor (bFGF) in uterine
leiomyomas. Int J Gynecol Pathol 2003;22(4):353-8
41. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell
proliferation and induction of apoptosis in uterine leiomyoma by
gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin
Endocrinol Metab 1998;84(4):1253-5
42. Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P
et al. Clinical response, vascular change, and angiogenesis in
gonadotropin-releasing hormone analogue-treated women with uterine
myomas. J Soc Gynecol Invest 2005;12(2):123-8
43. Lindsay PC, Shaw RW, Coelingh Bennink HJ, Kicovic P. The effect
of add-back treatment with tibolone (Livial) on patients treated with the
gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil
Steril 1996;65(2):342-8
44. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long term
administration of tibolone plus gonadotropin-releasing hormone agonist
123